TY - JOUR
T1 - Neurofibromatosis type 1 associated low grade gliomas
T2 - A comparison with sporadic low grade gliomas
AU - Helfferich, Jelte
AU - Nijmeijer, Ronald
AU - Brouwer, Oebele F.
AU - Boon, Maartje
AU - Fock, Annemarie
AU - Hoving, Eelco W.
AU - Meijer, Lisethe
AU - den Dunnen, Wilfred F. A.
AU - de Bont, Eveline S. J. M.
N1 - Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, associated with a variable clinical phenotype including cafe-au-lait spots, intertriginous freckling, Lisch nodules, neurofibromas, optic pathway gliomas and distinctive bony lesions. NF1 is caused by a mutation in the NF1 gene, which codes for neurofibromin, a large protein involved in the MAPK- and the mTOR-pathway through RAS-RAF signalling. NF1 is a known tumour predisposition syndrome, associated with different tumours of the nervous system including low grade gliomas (LGGs) in the paediatric population. The focus of this review is on grade I pilocytic astrocytomas (PAs), the most commonly observed histologic subtype of low grade gliomas in NF1. Clinically, these PAs have a better prognosis and show different localisation patterns than their sporadic counterparts, which are most commonly associated with a KIAA1549:BRAF fusion.In this review, possible mechanisms of tumourigenesis in LGGs with and without NF1 will be discussed, including the contribution of different signalling pathways and tumour microenvironment. Furthermore we will discuss how increased understanding of tumourigenesis may lead to new potential targets for treatment. (C) 2016 The Author(s). Published by Elsevier Ireland Ltd.
AB - Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, associated with a variable clinical phenotype including cafe-au-lait spots, intertriginous freckling, Lisch nodules, neurofibromas, optic pathway gliomas and distinctive bony lesions. NF1 is caused by a mutation in the NF1 gene, which codes for neurofibromin, a large protein involved in the MAPK- and the mTOR-pathway through RAS-RAF signalling. NF1 is a known tumour predisposition syndrome, associated with different tumours of the nervous system including low grade gliomas (LGGs) in the paediatric population. The focus of this review is on grade I pilocytic astrocytomas (PAs), the most commonly observed histologic subtype of low grade gliomas in NF1. Clinically, these PAs have a better prognosis and show different localisation patterns than their sporadic counterparts, which are most commonly associated with a KIAA1549:BRAF fusion.In this review, possible mechanisms of tumourigenesis in LGGs with and without NF1 will be discussed, including the contribution of different signalling pathways and tumour microenvironment. Furthermore we will discuss how increased understanding of tumourigenesis may lead to new potential targets for treatment. (C) 2016 The Author(s). Published by Elsevier Ireland Ltd.
KW - Neurofibromatosis
KW - NF1 gene
KW - BRAF:KIAA1549 fusion
KW - Low grade glioma
KW - Pilocytic astrocytoma
KW - OPTIC PATHWAY GLIOMA
KW - NF1-ASSOCIATED PILOCYTIC ASTROCYTOMAS
KW - CHILDRENS ONCOLOGY GROUP
KW - OF-PEDIATRIC-ONCOLOGY
KW - NERVE SHEATH TUMORS
KW - BRAIN-STEM GLIOMAS
KW - HIT-LGG 1996
KW - NF1 GENE
KW - MOUSE MODEL
KW - PHASE-II
U2 - 10.1016/j.critrevonc.2016.05.008
DO - 10.1016/j.critrevonc.2016.05.008
M3 - Review article
C2 - 27263935
SN - 1040-8428
VL - 104
SP - 30
EP - 41
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
ER -